Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2021

Open Access 01-12-2021 | Malaria | Review

Insights from modelling malaria vaccines for policy decisions: the focus on RTS,S

Authors: Katya Galactionova, Thomas A. Smith, Melissa A. Penny

Published in: Malaria Journal | Issue 1/2021

Login to get access

Abstract

Mathematical models are increasingly used to inform decisions throughout product development pathways from pre-clinical studies to country implementation of novel health interventions. This review illustrates the utility of simulation approaches by reviewing the literature on malaria vaccine modelling, with a focus on its link to the development of policy guidance for the first licensed product, RTS,S/AS01. The main contributions of modelling studies have been in inferring the mechanism of action and efficacy profile of RTS,S; to predicting the public health impact; and economic modelling mainly comprising cost-effectiveness analysis. The value of both product-specific and generic modelling of vaccines is highlighted.
Appendix
Available only for authorised users
Literature
1.
2.
Walther M. Advances in vaccine development against the pre-erythrocytic stage of Plasmodium falciparum malaria. Expert Rev Vaccines. 2006;5:81–93.PubMedCrossRef
3.
4.
Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. 1995;171:1576–85.PubMedCrossRef
5.
Schellenberg D. An evaluation of the cluster-randomised pilot implementation of RTS,S/AS01 through routine health systems in moderate to high malaria transmission settings in Africa. In: The Malaria Vaccine Pilot Evaluation. Geneva, World Health Organization; 2018.
6.
RTS,S Clinical Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomized, controlled trial. Lancet. 2015;386:31–45.
7.
Malaria vaccine. WHO position paper-January 2016. Wkly Epidemiol Rec. 2016;91:33–51.
8.
9.
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R-S, Diarra M, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385:1005–17.PubMedCrossRef
10.
Ross R. The prevention of malaria. London: John Murray Publ; 1911.
11.
MacDonald G. Malariology: a comprehensive survey of all aspects of this group of diseases from a global standpoint. Philadelphia: W.B. Saunders Co.; 1957.
12.
Dietz K, Molineaux L, Thomas A. A malaria model tested in the African savannah. Bull World Health Organ. 1974;50:347–57.PubMedPubMedCentral
13.
Ballou WR, Sherwood JA, Neva FA, Gordon DM, Wirtz RA, Wasserman GF, et al. Safety and efficacy of a recombinant-DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987;1:1277–81.PubMedCrossRef
14.
Struchiner CJ, Halloran ME, Spielman A. Modeling malaria vaccines. I. New uses for old ideas. Math Biosci. 1989;94:87–113.PubMedCrossRef
15.
Halloran ME, Struchiner CJ, Spielman A. Modeling malaria vaccines. II. Population effects of stage-specific malaria vaccines dependent on natural boosting. Math Biosci. 1989;94:115–49.PubMedCrossRef
16.
Halloran ME, Struchiner CJ. Modeling transmission dynamics of stage-specific malaria vaccines. Parasitol Today. 1992;8:77–85.PubMedCrossRef
17.
Ghani AC, Sutherland CJ, Riley EM, Drakeley CJ, Griffin JT, Gosling RD, et al. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS ONE. 2009;4:e4383.PubMedPubMedCentralCrossRef
18.
Vogt-Geisse K, Ngonghala CN, Feng Z. The impact of vaccination on malaria prevalence: a vaccine-age-structured modeling approach. J Biol Syst. 2020;28:475–513.CrossRef
19.
White LJ, Maude RJ, Pongtavornpinyo W, Saralamba S, Aguas R, Van Effelterre T, et al. The role of simple mathematical models in malaria elimination strategy design. Malar J. 2009;8:212.PubMedPubMedCentralCrossRef
20.
Tun STT, von Seidlein L, Pongvongsa T, Mayxay M, Saralamba S, Kyaw SS, et al. Towards malaria elimination in Savannakhet, Lao PDR: mathematical modelling driven strategy design. Malar J. 2017;16:483.PubMedPubMedCentralCrossRef
21.
22.
Smith TA, Killeen J, Maire N, Ross A, Molineaux L, Tediosi F, et al. Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falciparum malaria: Overview. Am J Trop Med Hyg. 2006;75:1–10.PubMedCrossRef
23.
Smith T, Maire N, Ross A, Penny M, Chitnis N, Schapira A, Studer A, et al. Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology. 2008;135:1507–16.PubMedCrossRef
24.
Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, et al. Ensemble modeling of the likely public health impact of a pre- erythrocytic malaria vaccine. PLoS Med. 2012;9:e1001157.PubMedPubMedCentralCrossRef
25.
26.
Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med Hyg. 2006;75:111–8.PubMedCrossRef
27.
Maire N, Aponte JJ, Ross A, Thompson R, Alonso P, Utzinger J, et al. Modeling a field trial of the RTS, S/AS02A malaria vaccine. Am J Trop Med Hyg. 2006;75:104–10.PubMedCrossRef
28.
Ross A, Killeen GF, Smith T. Relationships of host infectivity to mosquitoes and asexual parasite density in Plasmodium falciparum. Am J Trop Med Hyg. 2006;75(Suppl 2):32–7.PubMedCrossRef
29.
Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J. 2009;8:31.PubMedPubMedCentralCrossRef
30.
Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010;7:e1000324.PubMedPubMedCentralCrossRef
31.
Eckhoff P. Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings. Am J Trop Med Hyg. 2013;88:817–27.PubMedPubMedCentralCrossRef
32.
Sauboin CJ, Van Bellinghen LA, Van De Velde N, Van Vlaenderen I. Potential public health impact of RTS, S malaria candidate vaccine in sub-Saharan Africa: a modelling study. Malar J. 2015;14:524.PubMedPubMedCentralCrossRef
33.
Moorthy VS, Hutubessy R, Newman RD, Hombach J. Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses. Bull World Health Organ. 2012;90:864–6.PubMedPubMedCentralCrossRef
34.
Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health impact and cost-effectiveness of the RTS, S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387:367–75.PubMedPubMedCentralCrossRef
35.
Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS ONE. 2008;3:e3193.PubMedPubMedCentralCrossRef
36.
Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011;11:102–9.PubMedPubMedCentralCrossRef
37.
White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, et al. The relationship between RTS, S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PLoS ONE. 2013;8:e61395.PubMedPubMedCentralCrossRef
38.
White MT, Verity R, Giffin JT, Asante KP, Owusu-Agyei S, Geenwood B, et al. Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15:1450–8.PubMedPubMedCentralCrossRef
39.
Winskill P, Walker PGT, Griffin JT, Ghani AC. Modelling the cost-effectiveness of introducing the RTS, S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa. BMJ Glob Health. 2017;2:e000090.PubMedPubMedCentralCrossRef
40.
41.
Hogan AB, Winskill P, Ghani AC. Estimated impact of RTS, S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: a modelling study. PLoS Med. 2020;17:e1003377.PubMedPubMedCentralCrossRef
42.
Thompson HA, Hogan AB, Walker PGT, White MT, Cunnington AJ, Ockenhouse CF, et al. Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS, S/AS01 vaccination. Vaccine. 2020;38:7498–507.PubMedPubMedCentralCrossRef
43.
Penny MA, Pemberton-Ross P, Smith TA. The time-course of protection of the RTS, S vaccine against malaria infections and clinical disease. Malar J. 2015;14:437.PubMedPubMedCentralCrossRef
44.
Brooks A, Briet OJT, Hardy D, Steketee R, Smith TA. Simulated impact of RTS, S/AS01 vaccination programs in the context of changing malaria transmission. PLoS ONE. 2012;7:e32587.PubMedPubMedCentralCrossRef
45.
46.
Gandon S, Mackinnon M, Nee S, Read AF. Imperfect vaccines and the evolution of pathogen virulence. Nature. 2001;414:751–6.PubMedCrossRef
47.
Smith T. Imperfect vaccines and imperfect models. Trend Ecol Evol. 2002;17:154–6.CrossRef
48.
Hogan AB, Winskill P, Verity R, Griffin JT, Ghani AC. Modelling population-level impact to inform target product profiles for childhood malaria vaccines. BMC Med. 2018;16:109.PubMedPubMedCentralCrossRef
49.
Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA. The public health impact of malaria vaccine RTS, S in malaria endemic Africa: country-specific predictions using Phase III data and simulation models. BMC Med. 2015;13:170.PubMedPubMedCentralCrossRef
50.
Pemberton-Ross P, Smith TA, Hodel EM, Kay K, Penny MA. Age-shifting in malaria incidence as a result of induced immunological deficit. A simmulation study. Malar J. 2015;14:287.PubMedPubMedCentralCrossRef
51.
52.
Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle KE, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526:207–11.PubMedPubMedCentralCrossRef
53.
Camponovo F, Ockenhouse CF, Lee C, Penny MA. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. BMC Infect Dis. 2019;19:920.PubMedPubMedCentralCrossRef
54.
Penny MA, Camponovo F, Chitnis N, Smith TA, Tanner M. Future use-cases of vaccines in malaria control and elimination. Parasite Epidemiol Control. 2020;10:e00145.PubMedPubMedCentralCrossRef
55.
Yerushalmi E, Hunt P, Hoorens S, Sauboin C, Smith R. Exploring the use of a general equilibrium method to assess the value of a malaria vaccine: an application to Ghana. MDM Policy Pract. 2019;4:2381468319894345.PubMedPubMedCentral
56.
Hutton G, Tediosi F. The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania. Am J Trop Med Hyg. 2006;75:119–30.PubMedCrossRef
57.
58.
Galactionova K, Bertram M, Lauer J, Tediosi F. Costing RTS, S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: a generalizable approach drawing on publicly available data. Vaccine. 2015;33:6710–8.PubMedPubMedCentralCrossRef
59.
Sicuri E, Yaya Bocoum F, Nonvignon J, Alonso S, Fakih B, Bonsu G, et al. The costs of implementing vaccination with the RTS, S malaria vaccine in five sub-Saharan African countries. MDM Policy Pract. 2019;4:2381468319896280.PubMedPubMedCentral
60.
Tediosi F, Hutton G, Maire N, Ross A, Tanner M. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. Am J Trop Med Hyg. 2006;75:131–43.PubMedCrossRef
61.
Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the Expanded Program on Immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health. 2011;14:1028–38.PubMedCrossRef
62.
Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. The public health impact and cost-effectiveness of malaria vaccine candidate RTS, S/AS01: a systematic comparison of predictions from four mathematical models. In Report to MPAC/SAGE. Geneva: World Health Organization; 2015.
63.
Camponovo F, Bever CA, Galactionova K, Smith T, Penny MA. Incidence and admission rates for severe malaria and their impact on mortality in Africa. Malar J. 2017;16:1.PubMedPubMedCentralCrossRef
64.
Ndeketa L, Mategula D, Terlouw DJ, Bar-Zeev N, Sauboin CJ, Biernaux S. Cost-effectiveness and public health impact of RTS, S/AS01E malaria vaccine in Malawi, using a Markov static model. Wellcome Open Res. 2020;5:260.PubMedCrossRef
65.
66.
Galactionova K, Tediosi F, Camponovo F, Smith TA, Gething PW, Penny MA. Country specific predictions of the cost-effectiveness of malaria vaccine RTS, S/AS01 in endemic Africa. Vaccine. 2017;35:53–60.PubMedCrossRef
67.
Sauboin C, Van Bellinghen L-A, Van De Velde N, Van Vlaenderen I. Economic Impact of introducing the RTS, S malaria vaccine: cost-effectiveness and budget impact analysis in 41 countries. MDM Policy Pract. 2019;4:2381468319873324.PubMedPubMedCentral
68.
Winskill P, Walker P, Patouillard E, Cibulskis R, Ghani A. Prioritizing the scale up of interventions for malaria control and elimination. Am J Trop Med Hyg. 2018;99:328–9.
69.
Sauboin C, Van Vlaenderen I, Van Bellinghen LA, Standaert B. Reducing malaria mortality at the lowest budget: an optimization tool for selecting malaria preventative interventions applied to Ghana. MDM Policy Pract. 2019;4:2381468319861346.PubMedPubMedCentral
70.
Killeen GF, Smith TA, Ferguson HM, Mshinda H, Abdulla S, Lengeler C, et al. Preventing childhood malaria in Africa by protecting adults from mosquitoes with insecticide-treated nets. PLoS Med. 2007;4:e229.PubMedPubMedCentralCrossRef
71.
72.
Nunes JK, Cardenas V, Loucq C, Maire N, Smith T, Shaffer C, et al. Modeling the public health impact of malaria vaccines for developers and policymakers. BMC Infect Dis. 2013;13:295.PubMedPubMedCentralCrossRef
Metadata
Title
Insights from modelling malaria vaccines for policy decisions: the focus on RTS,S
Authors
Katya Galactionova
Thomas A. Smith
Melissa A. Penny
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Malaria
Published in
Malaria Journal / Issue 1/2021
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-021-03973-y

Other articles of this Issue 1/2021

Malaria Journal 1/2021 Go to the issue

Research

Malaria diagnosis in a malaria non-endemic high-resource country: high variation of diagnostic strategy in clinical laboratories in the Netherlands

Publisher Correction

Publisher Correction to: Direct contact between Plasmodium falciparum and human B-cells in a novel co-culture increases parasite growth and affects B-cell growth

Research

Evaluation of pilot implementation of seasonal malaria chemoprevention on morbidity in young children in Northern Sahelian Ghana

Research

Naturally induced humoral response against Plasmodium vivax reticulocyte binding protein 2P1

Research

Molecular and morphological identification of suspected Plasmodium vivax vectors in Central and Eastern Sudan

Research

Genetic diversity of Plasmodium falciparum populations in three malaria transmission settings in Madagascar
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits